RecruitingPhase 3NCT07357415

A Study of Retatrutide (LY3437943) in Participants Without Type 2 Diabetes Who Have Obesity or Overweight

A Phase 3b Study to Investigate the Efficacy and Safety of Different Retatrutide Dose Escalation Schemes in Participants Without Type 2 Diabetes Who Have Obesity or Overweight: A Randomized, Controlled, Double-Blind Trial

Sponsor

Eli Lilly and Company

Enrollment

600 participants

Start Date

Jan 24, 2026

Study Type

INTERVENTIONAL

Conditions

Obesity Overweight

Summary

The purpose of this study is to investigate the efficacy and safety of different retatrutide dose escalation schemes in participants without type 2 diabetes who have obesity or overweight. Participation in the study will last about 113 weeks.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study is testing a weight-loss drug called retatrutide (also known as LY3437943) to see how well it works for people with obesity or overweight who do not have type 2 diabetes. **You may be eligible if...** - Your body mass index (BMI) is 30 or higher, OR - Your BMI is 27 or higher and you also have high blood pressure, abnormal cholesterol, sleep apnea, or heart disease - You have tried to lose weight through dieting at least once without long-term success **You may NOT be eligible if...** - Your weight has changed by more than 11 pounds (5 kg) in the last 3 months - You have had or plan to have weight-loss surgery - You have type 1 or type 2 diabetes - You or a close family member has had a type of thyroid cancer called medullary thyroid carcinoma, or a condition called MEN-2 - You have had a heart attack, stroke, or were hospitalized for heart problems in the last 3 months - You have a history of pancreatitis - You have taken any weight-loss medication in the past 3 months Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGRetatrutide

Administered SC

Locations(35)

Arizona Research Center

Phoenix, Arizona, United States

Care Access - Huntington Beach

Huntington Beach, California, United States

Los Angeles Institute for Metabolic Research

Los Angeles, California, United States

New Horizon Research Center

Miami, Florida, United States

Encore Medical Research - Weston

Weston, Florida, United States

Pacific Diabetes & Endocrine Center

Honolulu, Hawaii, United States

L-MARC Research Center

Louisville, Kentucky, United States

Brigham and Women's Hospital Diabetes Program

Boston, Massachusetts, United States

Great Lakes Research Group, Inc.

Bay City, Michigan, United States

NYC Research INC

Long Island City, New York, United States

Weill Cornell Medical College

New York, New York, United States

Care Access - Raleigh

Raleigh, North Carolina, United States

New Phase Research and Development

Knoxville, Tennessee, United States

Velocity Clinical Research, Dallas

Dallas, Texas, United States

Cedar Health Research - Texas Native Health

Dallas, Texas, United States

Cedar Health Research

Dallas, Texas, United States

Cedar Health Research - Fort Worth

Fort Worth, Texas, United States

Advanced Research Institute

Ogden, Utah, United States

Dominion Medical Associates, Inc.

Richmond, Virginia, United States

CAMC Institute for Academic Medicine

Charleston, West Virginia, United States

Cicemo Srl

Buenos Aires, Argentina

CARDIAMET Investigaciones Médicas

Buenos Aires, Argentina

Stat Research S.A.

Buenos Aires, Argentina

Centro de Investigaciones Metabólicas (CINME)

Buenos Aires, Argentina

Centro Médico Viamonte

Buenos Aires, Argentina

Aggarwal and Associates Limited

Brampton, Canada

Med Trust Research

Courtice, Canada

Winterberry Research Inc.

Hamilton, Canada

Diex Recherche Inc. Division Joliette

Joliette, Canada

Milestone Research Inc.

London, Canada

Diex Recherche Inc. Division Quebec

Québec, Canada

Diex Recherche Inc. Division Sherbrooke

Sherbrooke, Canada

Canadian Phase Onward

Toronto, Canada

Dr. Anil K. Gupta Medicine Professional Corporation

Toronto, Canada

C.I.C. Mauricie inc.

Trois-Rivières, Canada

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07357415

Related Trials

Characterization of Patients With Uncommon Presentations and/or Uncommon Diseases Associated With the Cardiovascular System

NCT011434543 locations

Heart Health Study in Washington D.C. to Develop a Community-Based Behavioral Weight Loss Intervention

NCT019277831 location

Diabetes and Heart Disease Risk in Blacks

NCT000018531 location

Investigating the Impact of Obesity on Pubertal Development in Girls

NCT025836461 location

Efficacy and Safety of KAI-9531 in Participants Living With Obesity or Overweight With Weight-Related Comorbidities Who Do Not Have Diabetes

NCT0728487533 locations